Psoriatic Arthritis
Conference Coverage
Are repeat radiographs necessary in rheumatoid and psoriatic arthritis?
“If a patient doesn’t achieve remission or very low disease activity, obtaining a radiograph doesn’t change what you do because the patient’s not...
Conference Coverage
PsA prediction tool approaches clinical utility
A tool to identify patients with psoriasis at high risk of psoriatic arthritis appears near to clinical application.
Feature
Health plans get very poor scores for access to autoimmune drugs
Three out of four insurance plans use policies that result in significant to severe restriction of access to medications for seven autoimmune...
From the Journals
Nearly 12% of PsA patients need musculoskeletal surgery
Higher levels of joint damage increased the risk for disease-related surgical procedures.
Latest News
First Humira biosimilar launches in U.S.
Amgen’s Amjevita will be offered at 5% and 55% below Humira’s list price, but patients may not benefit from the more significant discount.
From the Journals
Fluorescence-optical imaging may detect preclinical PsA
Identification of microscopic blood vessel changes may point to psoriatic arthritis before clinical symptoms appear.
Commentary
75 years: A look back on the fascinating history of methotrexate and folate antagonists
Dr. David Warmflash recounts how the meandering path of early research into chemotherapy for hematologic malignancies later led to methotrexate’s...
From the Journals
Psoriasis, psoriatic arthritis show distinctive skin microbiomes
No significant microbiome differences were noted between lesional and nonlesional skin swab samples from patients with psoriasis and psoriatic...
Latest News
Topical psoriasis treatments
When using topical treatments, combination therapy is generally more effective than monotherapy for psoriasis, especially for plaque psoriasis, Dr...
Latest News
FDA will review pediatric indication for roflumilast cream
The indication under review is for treating psoriasis in children aged 2-11 years.
News from the FDA/CDC
FDA approves Idacio as eighth adalimumab biosimilar in U.S.
Data for Idacio (adalimumab-aacf) showed safety, efficacy, and immunogenicity similar to Humira.